CatSci Ltd, an award-winning innovation partner for medicines development, are pleased to share that Carlos R. Côté has joined the team as a Senior Business Development Manager in Boston, US. Committed to offering more and better to our global customers, Carlos will be based in the North American region to enable our US customers to leverage his in-depth understanding of the drug development pathway and regulatory requirements. This will aid them to successfully deliver their small molecule and oligonucleotides pipeline.
Carlos brings 15 years of experience in both drug development and business development, having previously been a Business Development Executive at a CDMO, and SiliCycle for 12 years before that. Throughout his career, Carlos has supported clients to advance their assets, spanning from academia and biotechs to medium and large pharmaceutical companies. He has worked on projects at every stage of drug development ranging from the initial research and discovery through to drug substance, formulation and drug product. He successfully delivered a fast-tracked oncology project of a large pharma company from Phase I to commercialisation.
Carlos’ in-depth knowledge of customers’ fundamental business needs, including funding, VC, milestones, out-licensing, ensures projects are always developed on time, in budget, and to the requisite quality. No matter which stage our customers are in in their journey, CatSci’s expert drug development capabilities along with Carlos’ experience will enable them to deliver affordable, best-in-class small molecule and oligonucleotide therapeutics to meet the evolving healthcare needs of the world.
Carlos says: “I am thrilled to be joining the CatSci team; I am looking forward to leveraging my expertise to enable our partners, both present and future, drive excellence in medicines development. It is an honour to be joining such a passionate team of experts dedicated to solving complex chemistry problems. I am excited to be part of CatSci’s journey as we work towards our common goal of getting medicines into the hands of patients in need.”
Jerome Theobald, CatSci’s Chief Operating Officer, says: “It is a great privilege to welcome Carlos to the CatSci team. Both his pharmaceutical market understanding and commercial acumen will accelerate our customers’ journey to the clinic. CatSci is going from strength-to-strength in our evolution, and Carlos’ appointment will only further our mission to expedite the development and manufacture of life changing therapeutics.”
